170 related articles for article (PubMed ID: 36499357)
61. PPI-Detect: A support vector machine model for sequence-based prediction of protein-protein interactions.
Romero-Molina S; Ruiz-Blanco YB; Harms M; Münch J; Sanchez-Garcia E
J Comput Chem; 2019 Apr; 40(11):1233-1242. PubMed ID: 30768790
[TBL] [Abstract][Full Text] [Related]
62. Non-resolving jaundice: bilirubin covalently attached to serum albumin circulates with the same metabolic half-life as albumin.
Reed RG; Davidson LK; Burrington CM; Peters T
Clin Chem; 1988 Oct; 34(10):1992-4. PubMed ID: 3168209
[TBL] [Abstract][Full Text] [Related]
63. R5X4 viruses are evolutionary, functional, and antigenic intermediates in the pathway of a simian-human immunodeficiency virus coreceptor switch.
Tasca S; Ho SH; Cheng-Mayer C
J Virol; 2008 Jul; 82(14):7089-99. PubMed ID: 18480460
[TBL] [Abstract][Full Text] [Related]
64. The structure of monomeric components of self-assembling CXCR4 antagonists determines the architecture of resulting nanostructures.
Lee Y; Chen Y; Tarasova NI; Gaponenko V
Nanotechnology; 2011 Dec; 22(50):505101. PubMed ID: 22107755
[TBL] [Abstract][Full Text] [Related]
65. Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.
De Clercq E; Schols D
Antivir Chem Chemother; 2001; 12 Suppl 1():19-31. PubMed ID: 11594685
[TBL] [Abstract][Full Text] [Related]
66. The effect of a phosphodiester linking group on albumin binding, blood half-life, and relaxivity of intravascular diethylenetriaminepentaacetato aquo gadolinium(III) MRI contrast agents.
McMurry TJ; Parmelee DJ; Sajiki H; Scott DM; Ouellet HS; Walovitch RC; Tyeklár Z; Dumas S; Bernard P; Nadler S; Midelfort K; Greenfield M; Troughton J; Lauffer RB
J Med Chem; 2002 Aug; 45(16):3465-74. PubMed ID: 12139457
[TBL] [Abstract][Full Text] [Related]
67. Suppression of multiclade R5 and X4 human immunodeficiency virus type-1 infections by a coreceptor-based anti-HIV strategy.
Nakayama D; Misumi S; Mukai R; Tachibana K; Umeda M; Shibata H; Takamune N; Shoji S
J Biochem; 2005 Nov; 138(5):571-82. PubMed ID: 16272569
[TBL] [Abstract][Full Text] [Related]
68. The CXCR4 agonist ligand stromal derived factor-1 maintains high affinity for receptors in both Galpha(i)-coupled and uncoupled states.
Di Salvo J; Koch GE; Johnson KE; Blake AD; Daugherty BL; DeMartino JA; Sirotina-Meisher A; Liu Y; Springer MS; Cascieri MA; Sullivan KA
Eur J Pharmacol; 2000 Dec; 409(2):143-54. PubMed ID: 11104827
[TBL] [Abstract][Full Text] [Related]
69. HIV co-receptors as targets for antiviral therapy.
Schols D
Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
[TBL] [Abstract][Full Text] [Related]
70. The molecular basis for the prolonged blood circulation of lipidated incretin peptides: Peptide oligomerization or binding to serum albumin?
Wang Y; Lomakin A; Kanai S; Alex R; Belli S; Donzelli M; Benedek GB
J Control Release; 2016 Nov; 241():25-33. PubMed ID: 27578099
[TBL] [Abstract][Full Text] [Related]
71. Next generation sequencing reveals a high frequency of CXCR4 utilizing viruses in HIV-1 chronically infected drug experienced individuals in South Africa.
Matume ND; Tebit DM; Gray LR; Hammarskjold ML; Rekosh D; Bessong PO
J Clin Virol; 2018 Jun; 103():81-87. PubMed ID: 29661652
[TBL] [Abstract][Full Text] [Related]
72. Lithocholic Acid-Based Peptide Delivery System for an Enhanced Pharmacological and Pharmacokinetic Profile of Xenopus GLP-1 Analogs.
Han J; Chen X; Zhao L; Fu J; Sun L; Zhang Y; Zhou F; Fei Y
Mol Pharm; 2018 Jul; 15(7):2840-2856. PubMed ID: 29799205
[TBL] [Abstract][Full Text] [Related]
73. A synthetic bivalent ligand of CXCR4 inhibits HIV infection.
Xu Y; Duggineni S; Espitia S; Richman DD; An J; Huang Z
Biochem Biophys Res Commun; 2013 Jun; 435(4):646-50. PubMed ID: 23688427
[TBL] [Abstract][Full Text] [Related]
74. Inhibitory role of CXCR4 glycan in CD4-independent X4-tropic human immunodeficiency virus type 1 infection and its abrogation in CD4-dependent infection.
Kubo Y; Yokoyama M; Yoshii H; Mitani C; Tominaga C; Tanaka Y; Sato H; Yamamoto N
J Gen Virol; 2007 Nov; 88(Pt 11):3139-3144. PubMed ID: 17947541
[TBL] [Abstract][Full Text] [Related]
75. Development of a receptor-targeted gene delivery system using CXCR4 ligand-conjugated cross-linking peptides.
Egorova A; Bogacheva M; Shubina A; Baranov V; Kiselev A
J Gene Med; 2014; 16(11-12):336-51. PubMed ID: 25382058
[TBL] [Abstract][Full Text] [Related]
76. Phosphate ester serum albumin affinity tags greatly improve peptide half-life in vivo.
Zobel K; Koehler MF; Beresini MH; Caris LD; Combs D
Bioorg Med Chem Lett; 2003 May; 13(9):1513-5. PubMed ID: 12699744
[TBL] [Abstract][Full Text] [Related]
77. Irreversible alkylation of human serum albumin by zileuton metabolite 2-acetylbenzothiophene-S-oxide: a potential model for hepatotoxicity.
Li F; Chordia MD; Woodling KA; Macdonald TL
Chem Res Toxicol; 2007 Dec; 20(12):1854-61. PubMed ID: 17944539
[TBL] [Abstract][Full Text] [Related]
78. RGD-human serum albumin conjugates as efficient tumor targeting probes.
Chen K; Xie J; Chen X
Mol Imaging; 2009; 8(2):65-73. PubMed ID: 19397852
[TBL] [Abstract][Full Text] [Related]
79. Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides.
Zorzi A; Middendorp SJ; Wilbs J; Deyle K; Heinis C
Nat Commun; 2017 Jul; 8():16092. PubMed ID: 28714475
[TBL] [Abstract][Full Text] [Related]
80. Structure-function relationship of novel X4 HIV-1 entry inhibitors - L- and D-arginine peptide-aminoglycoside conjugates.
Hegde R; Borkow G; Berchanski A; Lapidot A
FEBS J; 2007 Dec; 274(24):6523-36. PubMed ID: 18028446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
